The Effect of Human Leukocyte Antigen Macthing on Guiding Tacrolimus Regimen After Liver Transplantation
NCT ID: NCT03147157
Last Updated: 2017-05-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
120 participants
INTERVENTIONAL
2017-05-31
2025-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Outcome of Liver Transplant Patients With Tacrolimus-based Immunosuppression
NCT03800576
Efficacy and Safety of Immunosuppressive Withdrawal After Pediatric Liver Transplantation
NCT06147375
Prospective, Multicenter Clinical Study of Prolonged-release Tacrolimus in Stable Pediatric Liver Transplant Recipients
NCT06183892
Reduction of Tacrolimus Dose in Association With Mycophenolate Mofetil After Liver Transplantation
NCT00151632
Twice-daily Tacrolimus and Everolimus Convert to Once-daily Tacrolimus and Everolimus in Liver Transplant Recipient
NCT03256864
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
research group,low MR group
tacrolimus regimen guided by HLA matching rate
tacrolimus regimen guided by HLA matching rate
required low,middle and high tacrolimus concentration in high,middle and low MR group respectively
observation group,low MR group
tacrolimus regimen is applied according to clinical experience
No interventions assigned to this group
research group,middle MR group
tacrolimus regimen guided by HLA matching rate
tacrolimus regimen guided by HLA matching rate
required low,middle and high tacrolimus concentration in high,middle and low MR group respectively
observation group,middle MR group
tacrolimus regimen is applied according to clinical experience
No interventions assigned to this group
research group,high MR group
tacrolimus regimen guided by HLA matching rate
tacrolimus regimen guided by HLA matching rate
required low,middle and high tacrolimus concentration in high,middle and low MR group respectively
observation group,high MR group
tacrolimus regimen is applied according to clinical experience
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
tacrolimus regimen guided by HLA matching rate
required low,middle and high tacrolimus concentration in high,middle and low MR group respectively
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The First Hospital of Jilin University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Guoyue Lv
Vice President
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LCPYJJ2017007
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.